Biotech Analysts Schmidt & Schimmer, along with Avidity Biosciences CEO Boyce, CSO Flanagan and CMO Hughes discuss the unmet need and opportunity in Facioscapulohumeral Muscular Dystrophy (FSHD) in an Analyst/Industry conference call to be held on May 21 at 1 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks
- Biotech Alert: Searches spiking for these stocks today
- Avidity Biosciences Welcomes Simona Skerjanec as New Director
- Avidity Biosciences files automatic mixed securities shelf
- Avidity Biosciences reports Q1 EPS (79c), consensus (78c)